Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial – ACR Open Rheumatology Commentary: Durable Efficacy for Drug Preventing Lung Progression in Systemic Sclerosis — One-year results sustained over another 48 weeks – MedPage Today (free registration required)  

The post RCT | Effect of Nintedanib on progression of systemic sclerosis-associated interstitial lung disease over 100 weeks. appeared first on Links Medicus.